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Abstract 
The various clinical manifestations of chronic mucocutaneous candidiasis (CMC) often result 
from acquired T-cell immunodeficiencies. More rarely, CMC results from inborn errors of 
immunity, the recent dissection of which has shed light on the molecular mechanisms of 
mucocutaneous immunity to Candida albicans. CMC may accompany various other 
infectious diseases in patients with almost any broad and profound T-cell primary 
immunodeficiency. By contrast, CMC is one of the few key infections in patients with 
autosomal dominant hyper IgE syndrome (mutations in STAT3), and in rare patients with 
autosomal recessive predisposition to mucocutaneous and invasive fungal infections 
(mutations in CARD9). In patients with mutations in STAT3 and CARD9, the development of 
IL-17-producing T cells is impaired. Moreover, CMC is the principal, if not only infection in 
patients with autosomal recessive autoimmune polyendocrinopathy syndrome-I (mutations in 
AIRE). Patients with this condition have high titers of neutralizing autoantibodies (auto-Abs) 
against the IL-17 cytokines IL-17A, IL-17F, and IL-22. Collectively, tThese data suggest that 
human IL-17A, IL-17F, and IL-22 are essential for mucocutaneous immunity to Candida 
albicans. They also suggest that the distinct syndrome of isolated CMC, without auto-
immunity or other infections, may be caused by inborn errors of IL-17 immunity. 
 
 Introduction  
Candidiasis, one of the most frequent fungal diseases in humans, is generally caused by 
Candida albicans [1]. This fungus is a commensal organism of the oro-gastrointestinal tract 
and the vulvovaginal cavity. However, in some individuals, C. albicans causes disease, either 
by infecting mucosal and epidermal surfaces (mucocutaneous candidiasis, which is typically 
chronic) or, more rarely, by disseminating in the blood (systemic candidiasis, which is 
typically acute) [2,3]. Patients with inherited or acquired disorders of granulocytes usually 
present systemic candidiasis, whereas patients with inherited or acquired disorders of T 
lymphocytes develop chronic mucocutaneous candidiasis (CMC) [3-5][4,5]. Various 
alterations of the internal (e.g. a central line) or peripheral (e.g. xerostomy) milieu may also 
predispose to invasive or mucocutaneous CMC. CMC is highly heterogeneous clinically, with 
recurrent and/or persistent infections of the upper gastro-intestinal mucosa, skin, and nails 
with C. albicans, which may respond poorly to anti-fungal treatment or relapse upon 
discontinuation of treatment [2,6]. The mucocutaneous lesions are not themselves life-
threatening, but they have been associated with intracranial aneurisms in several patients with 
CMC, at least in patients with isolated, unexplained CMC [7-9]. 
 
CMC is usually associated with many other, frequently more severe infections, particularly in 
patients with broad and profound inherited or acquired T-cell immunodeficiencies. 
Oropharyngeal infections with Candida species are commonly found in HIV-infected 
individuals [10,11]. Persistent oral candidiasis and other mucocutaneous fungal infections are 
also often observed in infants with severe combined immunodeficiency (SCID) [12-
16]{Casanova, 2007 #495}. T cells therefore play a critical role in protective immunity 
against mucocutaneous C. albicans infections [14,15,17]. By contrast, CMC is a prominent 
feature of hyper IgE syndrome (HIES), a complex primary immunodeficiency characterized 
by high levels of serum IgE, severe atopic dermatitis, connective tissue and skeletal 
abnormalities, recurrent skin and lung infections caused by Staphylococcus aureus, and CMC 
[18]. The typical form of HIES is autosomal dominant (AD) and caused by dominant-negative 
mutations in STAT3 [19,20]. A related syndrome without developmental features and with 
very mild CMC has been documented in a patient with autosomal recessive TYK2 deficiency 
[21]. 
 
CMC is also an important infectious phenotype in the rare patients displaying susceptibility to 
mucocutaneous and systemic fungal infections who carry autosomal recessive mutations in 
CARD9 [22]. It remains unclear whether dectinDectin-1 deficiency is the cause of a 
predisposition to fungal infections, including CMC [23]. CMC may also strike patients not 
prone to invasive candidiasis and normally resistant to most other infectious agents, including 
other fungi. Such patients include those with autoimmune polyendocrine type I syndrome 
(APS-I, also known as autoimmune polyendocrinopathy with candidiasis and ectodermal 
dystrophy, APECED) [24] and patients with CMC and thyroid diseases [25]. APS-I results 
from autosomal recessive mutations in the autoimmune regulator gene AIRE [26]. In addition, 
other patients present with a distinct syndrome of isolated CMC, with no other severe 
infectious or autoimmune disorder [2,27,28]. Abnormalities of T-cell immunity to C. albicans 
have occasionally been reported in these patients, but no genetic etiology has yet been 
identified [2,6,29-34]. 
 
In recent years, the molecular pathogenesis of CMC in patients with primary 
immunodeficiencies has begun to be deciphered{Conti, 2010 #513}. This process has been 
facilitated by the development of a mouse models for CMC [35] and the discovery of IL-17 
cytokines: IL-17A, IL-17F, IL-22 and IL-26 in humans [36,37]. Mouse IL-17 cytokines are 
essential for mucocutaneous immunity to C. albicans [5,38]. However, these cytokines are 
also essential for protective immunity to many other pathogens, including Gram-positive and 
Gram-negative bacteria, such as Staphylococcus, Klebsiella and Salmonella, in various 
tissues, including the respiratory and gastro-intestinal tracts [39-43]. Patients with mutations 
in STAT3 have been shown to lack IL-17-producing circulating T cells [44-46]{Minegishi, 
2009 #401; Renner, 2008 #511}, patients with mutations in CARD9 have been shown to have 
significantly lower than normal proportions of IL-17-producing T cells [22] and patients with 
mutations in AIRE have high titers of neutralizing auto-Abs against IL-17 cytokines [47,48]. 
We review here the published studies of inborn errors of immunity conferring CMC, 
collectively identifying IL-17 cytokines as essential components of human mucocutaneous 
immunity to C. albicans. 
 
AD-HIES syndrome 
Cutaneous and pulmonary staphylococcal diseases affect most, if not all patients with AD-
HIES, but CMC is the second most frequent presentation, affecting about 80% of AD-HIES 
patients [18,49-51] [18,49,51]. CMC generally manifests as oral thrush, onychomycosis, 
and/or vaginal candidiasis, cases of median rhomboid glossitis have also been reported [51]. 
Dermatophytosis has also been described in some patients. In 2007, dominant-negative 
mutations in the STAT3 gene, encoding signal transducer and activator of transcription 3, were 
found to be responsible for AD-HIES [19,20]. STAT3 regulates multiple cytokine signaling 
pathways, including IL-6, IL-21, and IL-23, which are involved in the development of IL-17-
producing T cells in mice [36,52,53]. Several groups investigated the presence of IL-17-
producing T cells in STAT3-deficient patients with AD-HIES, based on the findings that 
mouse IL-17-producing T cells play a role in immunity to both systemic and mucosal C. 
albicans infection [38,54,55], these T cells are involved in skin and mucosal host defense 
[56,57], and mouse STAT3-deficient CD4+ T cells are unable to differentiate into IL-17-
producing T cells [58]. In From2008 onwards, threefive studies documented an almost 
complete lack of circulating IL-17-producing T cells in patients heterozygous for STAT3 
mutations, as assessed ex vivo [44-46] {Minegishi, 2009 #401; Renner, 2008 #511} . T cells 
from PBMCs or naive CD4+ T cells were unable to differentiate in vitro into memory 
CD4+/IL-17+ T cells in response to stimulation with various cytokines [44-46]. This lack of 
differentiation was associated with the impaired induction of RORγt mRNA upon stimulation 
of the patients’ CD4+ T cells, suggesting an intrinsic T-cell defect [44,45]. Two studiesThree 
studies reported a concomitant decrease in IL-22 production [45,46]{Minegishi, 2009 #401; 
Renner, 2008 #511}, whereas a third fourth did not [44]. The other IL-17 cytokines, IL-17F 
and IL-26, were not studied. The strong impairment of T-cell differentiation seemed to be 
specific to IL-17-producing T cells, although other lymphokines (such as IL-2 and IFN-γ) 
were also found to be affected, but to a lesser extent [44-46]. The proportion of circulating 
CD4+/CCR6+ T cells among PBMCs is low in AD-HIES patients, consistent with CCR6 being 
a marker of IL-17-producing T cells [59]. It is still unclear if TYK2 deficiency is associated 
with CMC, as a very mild form of mucocutaneous candidiasis was reported in the single 
TYK2-deficient patient described so far. IL-17-producing T cells were not evaluated in this 
patient {Minegishi, 2006 #456}. In any event, tThe identification of the genetic basis of AD-
HIES thus paved the way for cellular and molecular dissection of the pathogenesis of its 
associated CMC phenotype. 
 
IL-12p40 and IL-12Rβ1 deficiencies 
Another study showed that IL-12p40- and IL-12Rβ1-deficient patients, displaying a lack of 
production and of response, respectively, to both IL-12 and IL-23 have smaller proportions of 
circulating IL-17-producing T cells than normal individuals, but that this deficiency is much 
milder than that in patients with AD-HIES [46]. IL-12p40- and IL-12Rβ1-deficient patients 
typically suffer from the syndrome of Mendelian susceptibility to mycobacterial diseases 
(MSMD), which has been historically recognized and characterized on the basis of selective 
predisposition to mycobacteria and Salmonella in otherwise healthy children and adults [60-
63] [62,63].. Nevertheless, it recently became apparent that about 25% of IL-12p40- and IL-
12Rβ1-deficient patients also suffer from mild signs of CMC (but not dermatophytosis), even 
when not clinically ill from other infections or on antibiotic treatment ([64], Carlos 
Rodriguez-Gallego et al. manuscript in preparation). This mild and surprising phenotype may 
be partly accounted for by the small proportion of IL-17-producing T cells in these patients, 
itself probably resulting from the abolition of signaling by IL-23, an important IL-17-inducing 
cytokine in the mouse model [65] (reviewed in {Conti, 2010 #513}). This is consistent with 
the apparent lack of CMC in other patients with MSMD and mutations impairing cellular 
IFN-γ responses [62]. The lack of overt staphylococcal disease in IL-12p40- and IL-12Rβ1-
deficient patients, by contrast to the situation observed in AD-HIES patients, may be due to 
the presence of a sufficiently high proportion of IL-17-producing T cells in IL-12p40- and IL-
12Rβ1-deficient patients. The almost complete lack of IL-17-producing T cells in patients 
heterozygous for STAT3 may therefore account for the susceptibility of these patients to both 
staphylococcal disease and CMC, the two key infections in such patients. This susceptibility 
may involved impairment of the recruitment of granulocytes to infected tissues and their 
activation, and of the induction of antimicrobial peptides in epithelial cells [42]. Consistent 
with this hypothesis, epithelial cells in the skin and lungs, the organs most frequently affected 
by staphylococcal disease and CMC in STAT3-deficient patients, have been shown 
specifically to require IL-17 stimulation for the induction of antimicrobial target genes 
[42,66]. 
 CARD9 deficiency  
Caspase recruitment domain-containing protein 9 (CARD9) is an adaptor acting downstream 
from C-type lectin receptors, such as Dectin-1 [67,68]. Dectin-1 recruits and activates the 
spleen tyrosine kinase SYK [69]. The Dectin-1/SYK complex then engages CARD9, 
promoting pro-inflammatory cytokine production by dendritic cells, thereby inducing the 
differentiation of T cells into IL-17-producing T cells [70]. Card9-deficient mice are 
susceptible to systemic C. albicans infection [68] and fail to mount a Candida-specific IL-17-
producing T-cell response [70]. In humans, autosomal recessive CARD9 deficiency (Q295X 
allele) was recently reported in a large multiplex Iranian kindred with CMC (oral and/or 
vaginal candidiasis), dermatophytosis, and invasive candidiasis, causing the death of at least 
two, and possibly three of the eight  patients with proven or probable CARD9 deficiency [22]. 
No history of severe bacterial or viral infection was reported. Heterozygous family members 
were healthy. CARD9 expression was not detected in homozygous patients and the mutant 
allele was shown to be loss-of-expression when used to transfect bone marrow-derived 
macrophages from Card9-deficient mice. Moreover, the expression of wild-type but not 
mutant human CARD9 restored Dectin-1 signaling in Card9-deficient cells. Patients also 
displayed significantly smaller than normal proportions of IL-17-expressing T cells [22], 
suggesting that CARD9 is involved in the maturation of T cells for IL-17 cytokine production. 
The much greater severity of CARD9 deficiency than of Dectin-1 deficiency (see below) 
suggests that the pathogenesis of mucosal and systemic fungal infections in CARD9 
deficiency involves receptors other than Dectin-1, such as Dectin-2, MINCLE, OSCAR, 
TREM-1 and, possibly, other as yet unknown receptors [71-74]. TLRs are unlikely to play a 
major role, as IRAK4- and MyD88-deficient patients do not present even mild forms of CMC 
[75-78] [76,78]. Overall, CARD9 deficiency is essentially an autosomal recessive trait 
conferring a predisposition to dermatophytosis and candidiasis, including both the 
mucocutaneous and systemic forms, possibly due, at least partly, to impaired IL-17 cytokine 
production. The presence of a sufficiently high proportion of IL-17-producing T cells may 
account for the lack of staphylococcal disease, and invasive candidiasis may involve other 
mechanisms in these patients.  Finally, it is tempting to speculate that the association of CMC 
with low proportions of IL-17-producing T cells in STAT3-, IL-12Rβ1-, and CARD9-
deficient patients may pave the way for treatment of CMC in these and possibly other patients 
with recombinant IL-17 cytokines. 
 
DECTIN-1 deficiency? 
Dectin-1, a C-type lectin cell-surface receptor expressed, in particular, by myeloid and 
epithelial cells, serves as a receptor for β-glucans, a major component of the yeast cell wall 
[79]. C. albicans recognition by Dectin-1 induces, via SYK and CARD9, the production of 
pro-inflammatory cytokines, thereby promoting the differentiation of naive T cells into cells 
producing IL-17 cytokines [70]. Dectin-1-deficient mice were shown to be susceptible to 
systemic C. albicans infection in one study [80] but not in another [81]. Recently, three 
human adult siblings with onychomycosis caused by Trichophyton rubrum (dermatophytosis) 
and vulvovaginitis caused by C. albicans were reported to be homozygous for a loss-of-
expression and loss-of-function DECTIN1 allele (Y238X) [23]. This appears to be a mild 
form of CMC, as vulvovaginitis caused by Candida is common in the population. The 
syndrome is apparently dominant or co-dominant, as the heterozygous parents had a milder, 
but similar clinical phenotype. A causal relationship between the DECTIN1 genotype and 
both the expression of Dectin-1 and the cellular responses to stimulation of this receptor with 
β-glucan or C. albicans has been established. In particular, heterozygous cells have a response 
profile intermediate between those of wild-type and Y238X-homozygous cells. Interestingly, 
the induction of IL-17-producing T cells is impaired in some experimental conditions, 
including stimulation with C. albicans. By contrast, the phagocytosis or killing of C. albicans 
by Dectin-1-deficient monocytes and granulocytes has been shown to be normal. However, no 
causal relationship between DECTIN1 homozygosity or heterozygosity and the clinical 
phenotypes of vulvovaginitis and onychomycosis has been demonstrated. Indeed, the Y238X 
DECTIN1 allele is a common polymorphism, with a frequency of around 7% in European 
populations and of up to 40% in the San population of South Africa ([23] and 
http://hapmap.ncbi.nlm.nih.gov/). In the absence of a population-based study, it is therefore 
premature to attribute any role to this mutant DECTIN1 allele in terms of host defenses 
against fungi, including C. albicans in particular. Further studies are required to determine 
whether Dectin-1 deficiency is a genetic etiology of CMC and/or other fungal diseases. In the 
mean time, it is premature to consider Dectin-1 deficiency as a bona fide primary 
immunodeficiency. In any event, even if Dectin-1 deficiency could be shown to confer a 
predisposition to fungal infections, as a dominant, co-dominant, or recessive trait, its clinical 
penetrance would be low. The available data show that Dectin-1 is largely redundant for 
protective immunity to fungi in human populations. 
 
APECED/APS-I syndrome 
APS-I/APECED is a rare autosomal recessive syndrome characterized by multiple 
autoimmune polyendocrinopathies, such as hypoparathyroidism and adrenal failure [82,83]. 
The genetic etiology of APS-I was identified in 1997, with mutations in the autoimmune 
regulator (AIRE)-encoding gene [84,85]. AIRE governs a T-cell tolerance pathway, by 
inducing the production, in the thymus and peripheral lymphoid organs, of transcripts 
encoding proteins normally present in various peripheral tissues [83,86], thereby triggering 
the deletion of autoreactive T cells. Human AIRE deficiency therefore results in 
overwhelming auto-immunity. Intriguingly, up to 90% of APECED patients develop early-
onset CMC. In 2006, high levels of neutralizing IgG auto-Abs against IFN-α and IFN-ω were 
found in APS-I patients [87]. These auto-Abs were unlikely to predispose the patients to 
CMC, as patients with STAT1 deficiency and impaired responses to IFN-α/β and patients 
with NEMO, UNC-93B or TLR3 deficiencies and impaired production of IFN-α/β [88-92] 
[91] do not present CMC. No more than mild manifestations of oral candidiasis were 
observed in the only known TYK2-deficient patient, whose cellular defects are not restricted 
to the IFN-α/β pathway [21]. In turn, the lack of severe viral diseases in APS-I patients 
probably reflects the compensatory role of other anti-viral IFNs. These studies nonetheless led 
two groups to detect high titers of neutralizing IgG auto-Abs against IL-17A, IL-17F and/or 
IL-22 (but not IL-26) in the plasma of almost 200 patients tested [47,48]. No such Abs were 
found in the plasma of the 90 healthy individuals, 54 unaffected heterozygous patients’ 
relatives and almost 200 other patients with other autoimmune/endocrine disorders tested. 
Auto-Abs against all other cytokines tested, including those known to cause distinct clinical 
syndromes, such as IL-6, IFN-γ, and GM-CSF [93-97], were undetectable. Remarkably, two 
patients with thymoma and CMC were found to have auto-Abs against IL-17 cytokines [48], 
unlike patients with thymoma without CMC, suggesting that the auto-Abs against IL-17 
cytokines were responsible for the CMC. Moreover, auto-Abs were found in some patients 
with APS-I but without CMC, and even before the onset of CMC in some cases, suggesting 
that these auto-Abs are probably a cause rather than an effect of CMC. However, although 
correlative [98], the high titers of neutralizing auto-Abs against IL-17 cytokines in APS-I 
patients are probably sufficient to account for CMC. Clearly, these findings pave the way for 
the treatment of CMC in these patients with B cell-depleting, CD20-specific monoclonal Abs. 
Immunosuppression was used reluctantly in APS-I patients, in part because of the fear to 
aggravate CMC. The discovery that CMC has an auto-immune basis suggests that 
immunosuppression, CD20 mAbs in particular, may actually improve CMC along with other 
auto-immune phenotypes in these patients. Interestingly, IL-17 cytokines are thought to be 
key auto-immune cytokines in the mouse model. The multiple and severe auto-immune 
phenotypes in APS-I patients develop despite neutralizing auto-Abs to IL-17 cytokines, 
indicating paradoxically that multiple auto-immune phenotypes are IL-17-independent, and 
implying that neutralization of IL-17 in patients without APS-I and with these or even 
possibly other auto-immune phenotypes may not be beneficial. Nevertheless, the treatment of 
APS-I patients with CD20 Abs and the ensuing recovery of IL-17 immunity might reveal new 
auto-immune phenotypes, which conversely may be IL-17-dependent and good targets for 
anti-IL-17 therapy in patients without APS-I.  
 
Conclusion 
Three human inborn errors of immunity (AD-HIES, CARD9 deficiency, and APS-1) are 
associated with CMC as a key infectious phenotype. Patients with AD-HIES are also 
vulnerable to other infections, including staphylococcal disease in particular, and patients with 
CARD9 deficiency are vulnerable to systemic candidiasis, whereas CMC seems to be the only 
infection of note in patients with APS-I. In patients with these three disorders, the 
pathogenesis of CMC seems to involve impaired IL-17 immunity, involving IL-17A, IL-17F, 
and/or IL-22. This conclusion is strongly correlative, but further human genetic studies are 
required to document the collective and individual impact of IL-17 cytokines in host defense. 
The investigation of patients with isolated CMC, with no other autoimmune or infectious 
phenotype, may be rewarding [34]. No genetic etiology has yet been identified in patients 
with isolated CMC. Definitive proof of the role of IL-17 cytokines in immunity to C. albicans 
infection must await the identification of patients with isolated CMC and inherited disorders 
specifically affecting IL-17 immunity [99,100]. 
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Figure legend. Inborn errors of mucocutaneous immunity to Candida albicans in 
humans 
 
The recognition of C. albicans by myeloid and epithelial receptors induces the production of 
pro-inflammatory cytokines. One such pathway is triggered by the Dectin-1-mediated 
recognition of the C. albicans cell wall component β-glucan, and is mediated by SYK and 
CARD9, which is also essential for other pathways (DECTIN-2, MINCLE, TREM-1, NOD 
etc). Pro-inflammatory cytokines, such as IL-6 and IL-23, activate T lymphocytes via STAT3, 
which induces production of the transcription factor ROR-γt and T-cell differentiation into IL-
17-producing T cells. These T cells express the skin and mucosa homing receptors CCR4 and 
CCR6, and secrete IL-21 and the IL-17 cytokines IL-17A, IL-17F, IL-22, and IL-26. These 
cytokines act locally to activate epithelial cells and to induce the recruitment and activation of 
granulocytes (e.g. by inducing anti-microbial peptides, such as β-defensins), thereby helping 
to clear the fungal infection. In patients with autosomal recessive CARD9 deficiency (pink), 
autosomal dominant STAT3 deficiency (blue), or in patients with autosomal recessive APS-I 
(mutations in AIRE, not represented here) with high titers of neutralizing autoantibodies 
against IL-17A, IL-17F, and IL-22 (purple), IL-17-mediated immunity is impaired, probably 
accounting for the greater susceptibility of these patients to CMC. It will not be possible to 
confirm this conclusion until CMC-causing mutations are found in the genes encoding 
individual IL-17 cytokines or their receptors. 
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